Diabetic retinopathy and retinopathy of prematurity are among the leading causes of vision impairment throughout the world. Both diseases are characterized by pathological angiogenesis, which severely impairs vision. Extracellular proteinases play important roles in endothelial cell migration during angiogenesis. Amino-terminal fragment (ATF) is an angiostatic molecule that targets the uPA/uPAR system and inhibits endothelial cell migration. The angiostatic effect of ATF has been demonstrated in models of cancer, but has never been assessed in pathological retinal neovascularization. Endostatin also has angiostatic effects on tumor growth and retinal neovascularization.
Introduction
Ocular neovascularization is a complication of numerous ophthalmic conditions including diabetic retinopathy, retinopathy of prematurity and neovascular age-related macular degeneration. Diabetic retinopathy and retinopathy of prematurity are among the leading causes of vision impairment throughout the world. In these diseases, capillaries sprout from existing retinal blood vessels, leading to severe hemorrhage. 1 Retinal neovascularization can be triggered by exposure to hypoxia. 2 Indeed, new capillaries grow to compensate for the lack of oxygen by increasing the vascular surface.
Several clinical treatments exist for retinal neovascularization. However, these treatments only have temporary effects and the recurrence of symptoms ultimately results in loss of vision. Thus, gene transfer offers a means of achieving local sustained delivery of therapeutic protein in the eye. Many studies have shown that angiostatic molecules can inhibit neovascularization. [3] [4] [5] Extracellular proteinases and their inhibitors play important roles in the regulation of endothelial cell migration and extracellular matrix remodeling during angiogenesis. Urokinase (uPA) and its high-affinity receptor (uPAR) seem to be critical for angiogenesis because they control cell motility, matrix remodeling and the bioavailability of angiogenic factors. Indeed, the binding of uPA to uPAR allows the generation of plasmin, which degrades some of the components of the extracellular matrix (ECM). Plasmin also amplifies proteolysis by converting inactive zymogens into active metalloproteinases. 6 By remodeling the ECM, uPA releases or activates numerous growth factors sequestered within the ECM such as vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2). 7, 8 Therefore, therapeutic molecules that disrupt the interaction between uPA and uPAR might be effective by targeting both cell invasiveness and angiogenesis.
uPA binds to uPAR via its light-chain fragment, 9 known as the amino-terminal fragment (ATF, residues 1-135). This interaction involves the EGF-like domain of the ATF and is species-restricted. As ATF binds to uPAR on cell surfaces, it disrupts the interaction between uPA and uPAR and inhibits uPA/uPAR-dependent angiogenesis. A recombinant adenovirus encoding the noncatalytic ATF of mouse uPA prevents lung carcinoma metastasis 10 and protects mice in a liver metastasis model of human colon carcinoma. 11 A marked reduction in tumoral neovascularization was observed in these experiments.
Another angiostatic molecule, endostatin, seems to interfere with the proteolysis of the ECM by downregulating the secretion of soluble uPA and by removing uPAR-associated uPA from the focal adhesion site. 12 Endostatin, the C-terminal fragment of collagen XVIII, inhibits tumor growth 13, 14 and ocular angiogenesis 15, 16 in an endothelial cell-specific manner. 17, 18 In this study, we used a replication-deficient adenovirus vector carrying the mATF or the endostatin gene coupled to human serum albumin (HSA) to improve the half-life of the therapeutic protein in the circulation. We investigated the angiostatic effect of mATF-HSA and mEndoHSA on retinal neovascularization in a murine model of proliferative retinopathy.
Results

Ad ATFHSA and Ad EndoHSA transduction
We used RT-PCR and Western blot to test the in vivo expression of ATFHSA and EndoHSA by adenoviruses. For each animal, the right eye was injected with the adenovirus, whereas the contralateral eye was not and served as a control.
We studied adenoviral gene expression by RT-PCR ( Figure 1a) . ATFHSA was detected in eyes that were injected with Ad ATFHSA but not in the uninjected groups or in the Ad CO1-injected groups. Similarly, EndoHSA was detected in eyes that were injected with Ad EndoHSA but not in the uninjected groups or in the Ad CO1-injected groups. Cyclophilin was used as an internal control and was expressed in all eyes.
The adenoviral protein was detected in vivo by Western blotting (Figure 1b) 
Qualitative and quantitative analysis of retinal neovascularization
We induced retinopathy by exposing mice (P7-P12) to high levels of oxygen (75%). This causes extensive retinal capillary closure. When mice are returned to normal conditions, retinal ischemia and VEGF-dependent preretinal neovascularization occur in 100% of animals. 19 Neovascular tufts developed between P17 and P21. After P21, no further proliferation occurred and new vessels regressed spontaneously. To optimize adenoviral expression (maximal until 7 days after injection according to Apparailly et al 20 ) and the development of the neovascular response, adenoviral vectors were injected at P12, when the mice were returned to normal air. Mice pups were killed at P19, when neovascular tufts were well established and transgene expression had started to decline.
To assess retinal neovascularization qualitatively after adenovirus injection, we enucleated and fixed vectortreated and control eyes from P19 pups. The eyes were then embedded in paraffin and cut into sections. After histological staining, we compared the injected eye and the uninjected contralateral eye (internal control) from each animal. Uninjected control eyes typically displayed abundant longitudinal and transverse aberrant microvessels in the vitreous space above the inner limiting membrane (ILM) (Figure 2b and c). Eyes injected with Ad ATFHSA or Ad EndoHSA contained dramatically fewer aberrant vessels ( Figure 2d and e, respectively). Isolectin B4 staining and FITC-perfused whole mount retinas confirmed the reproducibility of this model of retinal neovascularization (data not shown).
To quantify retinal neovascularization, we directly counted endothelial cells in the retinal vasculature ( Figure 3 ). Ad CO1-treated eyes contained fewer endothelial cell nuclei than did untreated eyes (AdCO1 4872 versus contralateral eyes 7471; Po0.0001). This may be due to vitreous traumatism or to the vector itself. Indeed, the DE1 adenoviral vector alone inhibits pathological and physiological angiogenesis. 16 Ad ATFHSA-and Ad EndoHSA-injected eyes displayed a lower degree of retinal neovascularization than the contralateral eyes (Ad ATFHSA 1471 versus contralateral eyes 6371, Po0.0001; AdEndoHSA 1472 versus contralateral eyes 7071, Po0.0001). Moreover, the injection of either Ad ATFHSA or Ad EndoHSA significantly reduced the neovascular response (n¼5; Po0.0001) when compared with the Ad CO1-treated group (data not shown). The mean endothelial cell counts were reduced by 78.1% in Ad ATFHSA-injected eyes compared with paired controls and by 79.2% in Ad EndoHSA-injected eyes compared with paired controls. 
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Discussion
Our data show that the adenovirus-mediated delivery of ATFHSA or EndoHSA reduces retinal neovascularization in a mouse model of hypoxia-induced neovascularization. The angiostatic activities of ATF and endostatin have already been described in numerous tumor models. 10, 11, 13, 15 This is the first time that AFT has been shown to have angiostatic activity in a model of retinal neovascularization. We showed that that local gene transfer and the expression of ATFHSA reduce retinal neovascularization by 78.1%. Furthermore, Ad Endo-HSA, a well-known angiostatic molecule, reduced retinal neovascularization by 79.2%.
By targeting the uPA/uPAR system, ATF prevents neovascularization by inhibiting endothelial cell migration. However, residual neovascularization (22%) still occurred. This incomplete inhibition may be explained by the fact that ATF inhibits only one step of the angiogenic process. Endostatin did not have a complete antiangiogenic effect either, as residual neovascularization was also observed (21%). In other studies, the inhibition of neovascularization by endostatin was of the same order (80%). 15 However, endostatin reduces angiogenesis by inhibiting different steps of the angiogenic process, such as endothelial cell proliferation, apoptosis and cell migration in response to VEGF. 21 In this model of retinal vascularization, VEGF plays a key role, as its expression is regulated during hyperoxia (downregulation) and hypoxia (upregulation). 22 It is possible that VEGF signaling is not completely blocked by endostatin. However, other factors, like IGF-1, TGF B and PDGF, 23, 24 contribute to retinal neovascularization in ischemic retinopathies and could be responsible for residual angiogenesis. Indeed, Ozaki et al 25 have totally inhibited retinal neovascularization in the same mouse model of retinal neovascularization by using a kinase inhibitor that targets VEGF and PDGF receptors.
The half-lives of ATF and endostatin are rather short due to their low molecular weights. To prolong the halflife of these molecules, we decided to conjugate them to HSA (produced and provided by Professor M Perricaudet). HSA was chosen as a pharmacological carrier for the following reasons: it is a long-lasting, neutral carrier that is already used for macromolecular drugs 26, 27 and it increases the half-life of a 179-residue rabbit peptide by 140-fold. 28 Apparailly et al 20 used the Ad ATFHSA in a model of arthritis. They found that the systemic injection of Ad ATFHSA decreased the incidence of arthritis and the severity of the disease by inhibiting angiogenesis. Moreover, in vitro assays have shown that the fusion with HSA does not alter the bioactivity of ATF. Thus, the HSA moiety does not reduce the bioactivity of ATF either in vitro or in vivo. The anti-ATFHSA immune response has been studied after systemic injection. 20 Although no side effects were observed following the injection of the vector, an immune response against HSA was detected. We hypothesize that an anti-HSA immune response exists in the eye, like for systemic administration, although the eye is a relatively closed system due to the blood-retinal barrier. However, in our model of retinal neovascularization, the neovascular response was transient. The neovascular complex started to develop during the period of relative hypoxia when mice were returned to normal air at P12. After P21, no further proliferation occurred and new vessels regressed spontaneously. To optimize adenoviral expression and the development of the neovascular response, we injected the vector at P12 when the mice were returned to normal air. Thus, the maximal expression of ATFHSA coincided with the development of new vessels. Adenoviral vectors rapidly provide high levels of expression and are therefore ideal for proving concepts. However, it would be very interesting to evaluate the angiostatic effects of these adenoviruses on animal models of definitive AdATFHSA reduces retinal neovascularization L Le Gat et al angiogenesis, as the human diseases we would like to target are characterized by definitive neovascularization and blindness. The search for effective treatments for retinal neovascular disorders, including diabetic retinopathy and retinopathy of prematurity, remains one of the greatest challenges in ophthalmology. Our data show that the adenovirus-mediated transfer of ATFHSA or EndoHSA significantly reduces retinal neovascularization in a mouse model of ischemic retinopathy. Additional studies are needed to assess the antiangiogenic effects of these two proteins in combination.
Materials and methods
Adenovirus vectors
The adenovirus vectors Ad ATFHSA and Ad Endohas were constructed and produced by Dr C Bouquet at UMR 8121 (Vectorologie et Transfert de Gène), which is directed by Professor M Perricaudet. 11 The construction of Ad ATFHSA is described in detail by Apparailly et al. 20 Briefly, these vectors are DE1-DE3 recombinant adenoviruses expressing the murine ATF or endostatin gene coupled to the HSA gene under the control of the cytomegalovirus (CMV) promoter. After recombinational cloning in E. coli, 29 the recombinant adenoviral genome was excised and used to transfect 293 cells by the Lipofectamine Plus-based procedure (Life Technologies), thus yielding Ad ATFHSA and Ad EndoHSA. The AdCO1 adenovirus is a control virus that is identical to Ad ATFHSA and Ad EndoHSA, except that it does not carry the therapeutic cassette. High-titer recombinant adenoviruses were amplified in 293 cells and purified on CsCl gradients. At least 10 11 PFU/ml of vector particles were obtained by this method.
The biological activity of Ad ATFHSA has been tested previously. 20 Ad EndoHSA has been shown to inhibit endothelial cell proliferation (C Bouquet, personal data). Genetic coupling of ATF or endostatin to HSA did not significantly reduce the ability of the ATF moiety to exert its bioactivity.
Murine model of oxygen-induced retinopathy
The well-established and reproducible murine model of oxygen-induced retinopathy was used to induce retinal neovascularization in mice pups. 19 All animals were treated in a humane manner and were handled in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice (7-day-old, P7) (C57Bl/6J, IFFA Credo, France) were placed in a 7572% oxygen atmosphere and maintained in this environment until P12. 19 During this time, the oxygen concentration was checked twice daily by an oxymeter (ZOA 100 oxygen analyser, ARELCO, France). At P12, mouse pups were returned to normoxic conditions. At P12, mice pups were given an intravitreal injection of adenoviral solution in their right eye. The controlateral eye was not injected. They were anesthetized by an intramuscular injection of 10 ml/g of weight of xylasine (Rompun 2%, 20 mg/ml) and Ketamine (Ketamine 1000 Virbac, 100 mg/ml) mixed 1:1:20 with distilled water. The palpebral fissure was then opened with microscissors and the pupil dilated with topical 0.5% Tropicamide (Mydriaticum s 0.5%, MSD). At P19 mice were killed and the eyes were rapidly removed. As the neovascular response was maximal between P17 and P2119 and adenoviral gene expression started to decline 7 days after injection, 20 we decided to kill mice pups at P19 to analyze retinal neovascularization.
ATFHSA and EndoHSA RT-PCR
At P17, the mice were killed and the eyes were rapidly enucleated. Four eyes from each group (AdCO1, Ad ATFHSA, Ad EndoHSA and contralateral eyes from each group) were homogenized in 1 ml of TRIzol s reagent (Life Technologies). mRNAs and proteins were extracted as described by the manufacturer. The resulting preparations were used for RT-PCR and Western blotting, respectively.
We compared the amounts of ATF-HSA or Endo-HSA mRNA with cyclophilin mRNA (internal control) in treated and untreated eyes. We used 1 mg of total RNA for reverse transcription using Superscript II RNase H-Reverse Transcriptase (Invitrogen, France) as recommended by the manufacturer. PCRs were performed using 1 ml of cDNA, ATFHSA or EndoHSA oligonucleotides (5 mM), cyclophilin oligonucleotides (0.1 mM), 1 Â Taq buffer and MgCl 2 (1.5 mM) and an annealing temperature of 551C. The predicted sizes of the PCR products were: 311 bp for the cyclophilin product, 570 bp for the ATFHSA product and 800 bp for the EndoHSA product. The 5 0 oligonucleotide was designed according to the ATF or endostatin sequence, whereas the 3 0 oligonucleotide was based on the HSA sequence. (Oligonucleotides for ATFHSA amplification: 5 0 gagcactgtgagatagatgc; 3 0 gccatttcaccataggtttc. Oligonucleotides for EndoHSA amplification: 5 0 ctgaaggacgaggtgct atc; 3 0 gaaaaggagttccggggcat. Oligonucleotides for cyclophilin amplification: 3 0 tccagcatttgccatggacaaga; 5 0 tggtc aaccccaccgtgttcttcg.)
ATFHSA and EndoHSA Western blotting
The positive control for this Western blot consisted of the supernatant from CHO cells infected with Ad ATFHSA, AdEndoHSA or AdCO1 (300 PFU/80% infected cells).
The extracted proteins were sonicated in 500 ml of RIPA buffer (150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris), 1% PMSF and 1% Proteinase Inhibitor cocktail (ROCHE). Proteins were quantified by a protein assay kit (DC Protein Assay; Bio-Rad Laboratories) according to the manufacturer's protocol.
For Western blot analysis, 80 mg of total protein was resuspended in sample buffer containing 10% b-mercapto ethanol (14.2 M) and 10% DTT (1 M). The samples were then denatured at 951C for 3 min. The samples were subjected to electrophoresis in 5% SDS-polyacrylamide gels. After blotting onto nitrocellulose membranes (Protran BA 83, Schleicher & Schuell), the membranes were placed for 30 min at room temperature in blocking buffer (3% nonfat dried milk, TBST (Tris-buffered AdATFHSA reduces retinal neovascularization L Le Gat et al saline containing 0.1% Tween-20)). The blots were then incubated with a murine anti-mouse urokinase (1:4000 dilution in blocking buffer; Kordia, Netherlands) or with a rabbit anti-mouse endostatin (1:100 dilution in blocking buffer; Abcyss, France) antibody at 41C overnight. After washing in TBST, the blots were incubated with horseradish peroxidase-conjugated anti-IgG (antimouse IgG 1:10 000 dilution or anti-rabbit IgG 1:10 000 dilution; Amersham) at room temperature for 2 h. Bound antibodies were detected by an enhanced chemiluminescence kit (ECL Western blot analysis system, Amersham Pharmacia Biotechnologies).
Qualitative and quantitative assessment of the retinal neovascularization
At P19, eyes (n¼5 for each injected and noninjected group) were enucleated, fixed in 4% paraformaldehyde, dehydrated through a graded series of alcohols and embedded in paraffin. Seven 5-mm sagittal sections, each 30 mm apart, from both sides of the optic nerve were stained with periodic acid, Schiff's reagent and hematoxylin.
The number of neovascular endothelial cell nuclei on the vitreous side of the ILM of the retina in each intact section was counted at Â 400 magnification using a masked protocol. The mean number of cell nuclei for each eye was calculated. The mean numbers of neovascular cell nuclei in each treatment group were compared. Statistical analysis was performed using Student's t test. A P-value of o0.05 was considered to be statistically significant.
